Minoli A. Perera

Minoli A. Perera

Auto-generated profile, based on publicly available information

Minoli A. Perera

Department of Pharmacology, Northwestern University, Chicago IL, 60611, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2011 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MPM A Perera
M A Perera
EGEric Gamazon
Eric Gamazon
LCL H Cavallari
L H Cavallari
SPS R Patel
S R Patel
SPS Poindexter
S Poindexter
NCN J Cox
N J Cox

30 April 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
HZHonghong Zhang
Honghong Zhang
TDTanima De
Tanima De
YZYizhen Zhong
Yizhen Zhong
MPMinoli A. Perera
Minoli A. Perera

1 June 2019 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
YZYizhen Zhong
Yizhen Zhong
MPMinoli A. Perera
Minoli A. Perera
EGEric Gamazon
Eric Gamazon

10 September 2013 in The Pharmacogenomics Journal
Verified
Journal Article
Open access
PDF file
WHW Hernandez
W Hernandez
EGEric Gamazon
Eric Gamazon
KAK Aquino-Michaels
K Aquino-Michaels
SPS Patel
S Patel
TOT J O'BRien
T J O'BRien
MPM A Perera
M A Perera
Using a derivation cohort (N=349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfarin dose requirement in African Americans (AAs). We tested our novel algorithm in an independent cohort of 129 AAs and compared the dose prediction to the International Warfarin Pharmacogenetics Consortium (IWPC) dosing algorithms. Our algorithm explains more of the phenotypic variation (R2=0.27) than the IWPC pharmacogenomics (R2=0.15) or clinical (R2=0.16) algorithms. Among high-dose patients, our algorithm predicted a higher proportion of patients within 20% of stable warfarin dose (45% vs 29% and 2% in the IWPC pharmacogenomics and clinical algorithms, respectively). In contrast to our novel algorithm, a significant inverse correlation between predicted dose and percent West African ancestry was observed for the IWPC pharmacogenomics algorithm among patients requiring 60 mg per week (β=−2.04, P=0.02).

2 October 2014 in Blood
Verified
Journal Article
Closed access
PDF file
RDRoxana Daneshjou
Roxana Daneshjou
EGEric Gamazon
Eric Gamazon
BBBen Burkley
Ben Burkley
LCLarisa H. Cavallari
Larisa H. Cavallari
JJJulie A. Johnson
Julie A. Johnson
MPMinoli A. Perera
Minoli A. Perera
The anticoagulant warfarin has >30 million prescriptions per year in the United States. Doses can vary 20-fold between patients, and incorrect dosing can result in serious adverse events. Variation in warfarin pharmacokinetic and pharmacodynamic genes, such as CYP2C9 and VKORC1, do not fully explain the dose variability in African Americans. To identify additional genetic contributors to warfarin dose, we exome sequenced 103 African Americans on stable doses of warfarin at extremes (≤35 and ≥49 mg/week). We found an association between lower warfarin dose and a population-specific regulatory variant, rs7856096 (P = 1.82 × 10−8, minor allele frequency = 20.4%), in the folate homeostasis gene folylpolyglutamate synthase (FPGS). We replicated this association in an independent cohort of 372 African American subjects whose stable warfarin doses represented the full dosing spectrum (P = .046). In a combined cohort, adding rs7856096 to the International Warfarin Pharmacogenetic Consortium pharmacogenetic dosing algorithm resulted in a 5.8 mg/week (P = 3.93 × 10−5) decrease in warfarin dose for each allele carried. The variant overlaps functional elements and was associated (P = .01) with FPGS gene expression in lymphoblastoid cell lines derived from combined HapMap African populations (N = 326). Our results provide the first evidence linking genetic variation in folate homeostasis to warfarin response. Key Points A population-specific genetic variant involved in folate homeostasis is associated with lower warfarin dose in African Americans.

14 April 2016 in Blood
Verified
Journal Article
Closed access
PDF file
WHWenndy Hernandez
Wenndy Hernandez
EGEric Gamazon
Eric Gamazon
ESErin Smithberger
Erin Smithberger
TOTravis J. O’brien
Travis J. O’brien
AHArthur F. Harralson
Arthur F. Harralson
MPMinoli A. Perera
Minoli A. Perera
Venous thromboembolism (VTE) is the third most common life-threatening cardiovascular condition in the United States, with African Americans (AAs) having a 30% to 60% higher incidence compared with other ethnicities. The mechanisms underlying population differences in the risk of VTE are poorly understood. We conducted the first genome-wide association study in AAs, comprising 578 subjects, followed by replication of highly significant findings in an independent cohort of 159 AA subjects. Logistic regression was used to estimate the association between genetic variants and VTE risk. Through bioinformatics analysis of the top signals, we identified expression quantitative trait loci (eQTLs) in whole blood and investigated the messenger RNA expression differences in VTE cases and controls. We identified and replicated single-nucleotide polymorphisms on chromosome 20 (rs2144940, rs2567617, and rs1998081) that increased risk of VTE by 2.3-fold (P < 6 × 10−7). These risk variants were found in higher frequency among populations of African descent (>20%) compared with other ethnic groups (<10%). We demonstrate that SNPs on chromosome 20 are cis-eQTLs for thrombomodulin (THBD), and the expression of THBD is lower among VTE cases compared with controls (P = 9.87 × 10−6). We have identified novel polymorphisms associated with increased risk of VTE in AAs. These polymorphisms are predominantly found among populations of African descent and are associated with THBD gene expression. Our findings provide new molecular insight into a mechanism regulating VTE susceptibility and identify common genetic variants that increase the risk of VTE in AAs, a population disproportionately affected by this disease. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Our study has identified common genetic risk factors for VTE among AAs. These risk factors are associated with decreased thrombomodulin gene expression, suggesting a mechanistic link.